During the past decade, UMHAT Dr. Georgi Stranski, EAD conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 24 clinical trials were completed, i.e. on average, 54.5% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 14 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UMHAT Dr. Georgi Stranski, EAD" #1 sponsor was "Janssen Research & Development, LLC" with 8 trials, followed by "Pfizer" with 8 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "Agios Pharmaceuticals, Inc." with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UMHAT Dr. Georgi Stranski, EAD" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "Gynecologic Oncology Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "UMHAT Dr. Georgi Stranski, EAD" are "Psoriasis" (5 trials), "Schizophrenia" (4 trials), "Arthritis, Psoriatic" (2 trials), "Atrial Fibrillation" (2 trials) and "Colitis, Ulcerative" (2 trials). Many other conditions were trialed in "UMHAT Dr. Georgi Stranski, EAD" in a lesser frequency.

Most popular intervention types in "UMHAT Dr. Georgi Stranski, EAD" are "Drug" (49 trials), "Biological" (5 trials), "Other" (4 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "CP-690,550" (2 trials), "Cariprazine" (2 trials), "Docetaxel" (2 trials) and "Guselkumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "UMHAT Dr. Georgi Stranski, EAD" are 50 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "UMHAT Dr. Georgi Stranski, EAD". undefined are not yet recruiting, 11 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in UMHAT Dr. Georgi Stranski, EAD, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in UMHAT Dr. Georgi Stranski, EAD, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".